Spring Creek Capital’s AEON Biopharma AEON Stock Holding History

Spring Creek Capital’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,472	Closed	-$2.44M	–	1
2022 Q1	$2.44M	Hold	3,472	–	–	0.1%	227
2021 Q4	$2.43M	Hold	3,472	–	–	0.09%	202
2021 Q3	$2.44M	Hold	3,472	–	–	0.12%	166
2021 Q2	$2.41M	Buy	+3,472	New	+$2.43M	0.12%	165

Other funds holding AEON

ECP

Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Spring Creek Capital's AEON Position: Q2 2022 in Review

Spring Creek Capital sold out of AEON Biopharma (AEON) in Q2 2022, closing a stake of 3,472 shares — an estimated $2.44M sold.

Spring Creek Capital first reported a position in AEON in Q2 2021 and held it in 4 quarters. The position peaked at $2.44M in Q1 2022. 73 funds tracked by Wall St. Rank hold AEON as of Q2 2022.

Spring Creek Capital reported no remaining AEON Biopharma position as of Q2 2022 after selling out during the quarter.
Spring Creek Capital sold 3,472 AEON Biopharma shares in Q2 2022, an estimated $2.44M.
Spring Creek Capital first reported a position in AEON Biopharma in Q2 2021 and held it in 4 quarters.
Spring Creek Capital's AEON Biopharma position peaked at $2.44M in Q1 2022.
73 funds tracked by Wall St. Rank held AEON Biopharma as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.